Testing the drug mix Opdualag for high-grade glioma and DIPG with a DNA repair problem
Official title: Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests how well people with a certain kind of brain tumor handle a mix of two drugs.
Read our full plain-language summary
What the trial team says
The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.
Key facts
- Registry number
- NCT07644312
- Stage of testing
- Phase 2
- Conditions studied
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair Deficient
Where it is running
No locations are listed for this trial. The trial's own page may have more.
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.